{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:21Z","timestamp":1786985061384,"version":"build-2736575974"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["TTK220324671"],"award-info":[{"award-number":["TTK220324671"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bbrep.2025.102345","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:57:21Z","timestamp":1762462641000},"page":"102345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review"],"prefix":"10.1016","volume":"44","author":[{"given":"Amogelang","family":"Sedibe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ntethelelo","family":"Sibiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Nyakudya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-1545","authenticated-orcid":false,"given":"Mlindeli","family":"Gamede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002648","article-title":"Discontinuation of tenofovir disoproxil fumarate from initial art regimens because of renal adverse events: an analysis of data from four multi-country clinical trials","volume":"4","author":"Ngongondo","year":"2024","journal-title":"PLOS Glob Public Health"},{"issue":"10","key":"10.1016\/j.bbrep.2025.102345_bib153","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","article-title":"Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain","volume":"36","author":"Kauppinen","year":"2022","journal-title":"Aids"},{"issue":"10","key":"10.1016\/j.bbrep.2025.102345_bib154","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (rpv), emtricitabine (ftc) and tenofovir alafenamide from either rpv, ftc and tenofovir disoproxil fumarate (tdf) or efavirenz, ftc and tdf: 96-week results from two randomized clinical trials","volume":"19","author":"Hagins","year":"2018","journal-title":"HIV Med."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib126","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bcpt.13161","article-title":"Treatment with tenofovir alafenamide fumarate worsens the lipid profile of hiv-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine","volume":"124","author":"Cid-Silva","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from tdf to taf in a u.S. cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J. Int. AIDS Soc."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib141","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciu234","article-title":"Lipid levels and changes in body fat distribution in treatment-naive, hiv-1-infected adults treated with rilpivirine or efavirenz for 96 weeks in the echo and thrive trials","volume":"59","author":"Tebas","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrep.2025.102345_bib135","first-page":"601","article-title":"Patient reported central nervous system adverse events of efavirenz-based antiretroviral therapy in people living with hiv in northwest ethiopia","volume":"12","author":"Muche","year":"2020","journal-title":"HIV AIDS (Auckl)"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"15","key":"10.1016\/j.bbrep.2025.102345_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158418","article-title":"Metabolic, mitochondrial, and inflammatory effects of efavirenz, emtricitabine, and tenofovir disoproxil fumarate in asymptomatic antiretroviral-na\u00efve people with hiv","volume":"25","author":"Barroso","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102345_bib139","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells10071687","article-title":"Nnrti and liver damage: evidence of their association and the mechanisms involved","volume":"10","author":"Benedicto","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib156","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/COH.0000000000000705","article-title":"An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors","volume":"16","author":"Senneker","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib146","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051246","article-title":"Lipidomics reveals reduced inflammatory lipid species and storage lipids after switching from efv\/ftc\/tdf to rpv\/ftc\/tdf: a randomized open-label trial","volume":"9","author":"Curran","year":"2020","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102345_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071454","article-title":"Rilpivirine activates stat1 in non-parenchymal cells to regulate liver injury in people living with hiv and masld","volume":"12","author":"Moragrega","year":"2024","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib150","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus\u20131 infection: week 48 results of the drive-ahead trial","volume":"68","author":"Orkin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrep.2025.102345_bib1","first-page":"507","article-title":"Antiretroviral therapy-associated metabolic complications: review of the recent studies","volume":"12","author":"Thet","year":"2020","journal-title":"HIV AIDS (Auckl)"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib2","article-title":"Hiv, antiretroviral therapy and metabolic alterations: a review","volume":"12","author":"Ergin","year":"2020","journal-title":"Cureus."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-3542(01)00148-6","article-title":"Metabolic complications associated with antiretroviral therapy","volume":"51","author":"Jain","year":"2001","journal-title":"Antiviral Res."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102345_bib4","article-title":"Renewing our focus on vulnerable populations among people living with hiv","volume":"9","author":"Ayieko","year":"2024","journal-title":"Trop. Med. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib5","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1186\/s12889-025-23121-4","article-title":"Global and regional disease burden of hiv\/aids from 1990 to 2021 and projections to 2030","volume":"25","author":"Lu","year":"2025","journal-title":"BMC Pub. Health."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib6","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2468-2667(24)00020-3","article-title":"Future hiv epidemic trajectories in South africa and projected long-term consequences of reductions in general population hiv testing: a mathematical modelling study","volume":"9","author":"Rautenbach","year":"2024","journal-title":"Lancet Pub. Health."},{"key":"10.1016\/j.bbrep.2025.102345_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijid.2020.09.011","article-title":"Ending the epidemic of hiv\/aids by 2030: will there be an endgame to hiv, or an endemic hiv requiring an integrated health systems response in many countries?","volume":"100","author":"Assefa","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102345_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272405","article-title":"Achieving the 95 95 95 targets for all: a pathway to ending aids","volume":"17","author":"Frescura","year":"2022","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12977-018-0408-3","article-title":"Pre-exposure prophylaxis (prep) in an era of stalled hiv prevention: can it change the game?","volume":"15","author":"Eakle","year":"2018","journal-title":"Retrovirol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s15010-015-0850-2","article-title":"Hiv pre-exposure prophylaxis (prep): a review of current knowledge of oral systemic hiv prep in humans","volume":"44","author":"Spinner","year":"2016","journal-title":"Infection."},{"issue":"113","key":"10.1016\/j.bbrep.2025.102345_bib11","first-page":"2","article-title":"Hiv co-morbidities and multi-morbidities","volume":"1","author":"Archer","year":"2016","journal-title":"HIV Curr Res"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020190","article-title":"Does the polypill improve patient adherence compared to its individual formulations? A systematic review","volume":"12","author":"Baumgartner","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-08083-2","article-title":"Follow-up of phenotype and metabolic changes in adult males living with hiv on combination antiretroviral therapy (cart) for a decade","volume":"15","author":"Satyakumar","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2025.102345_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fendo.2018.00514","article-title":"Insulin resistance in hiv-patients: causes and consequences","volume":"9","author":"Pedro","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"9833","key":"10.1016\/j.bbrep.2025.102345_bib15","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","article-title":"Prediabetes: a high-risk state for diabetes development","volume":"379","author":"Tab\u00e1k","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbrep.2025.102345_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103896","article-title":"Ageing with hiv: challenges and biomarkers","volume":"77","author":"Rod\u00e9s","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrep.2025.102345_bib17","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications","volume":"13","author":"Wondmkun","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib18","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/ijms25031882","article-title":"The role of obesity in type 2 diabetes mellitus\u2014an overview","volume":"25","author":"Chandrasekaran","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102345_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.bbrep.2025.102345_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2023.100087","article-title":"Obesity and malnutrition in children and adults: a clinical review","volume":"8","author":"Bradley","year":"2023","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.bbrep.2025.102345_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104754","article-title":"A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity","volume":"136","author":"Safaei","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbrep.2025.102345_bib22","article-title":"The global burden of overweight-obesity and its association with economic status, benefiting from steps survey of who member states: a meta-analysis","volume":"46","author":"Islam","year":"2024","journal-title":"Preventive Medicine Rep."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.amepre.2011.10.026","article-title":"Obesity and severe obesity forecasts through 2030","volume":"42","author":"Finkelstein","year":"2012","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.bbrep.2025.102345_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2955","article-title":"Type 2 diabetes: does pancreatic fat really matter?","volume":"34","author":"Guglielmi","year":"2018","journal-title":"Diabetes Metab Res Rev."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COH.0000000000000834","article-title":"The pathogenesis of obesity in people living with hiv","volume":"19","author":"Bailin","year":"2024","journal-title":"Curr. Opin. HIV AIDS."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","article-title":"Obesity and weight gain in persons with hiv","volume":"17","author":"Bailin","year":"2020","journal-title":"Curr. HIV AIDS Rep."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COH.0000000000000830","article-title":"Epidemiology of obesity among people with hiv","volume":"19","author":"Talathi","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40795-022-00604-w","article-title":"Prevalence of overweight and obesity and associated factors among people living with hiv attending a tertiary care clinic in uganda","volume":"8","author":"Nalugga","year":"2022","journal-title":"BMC Nutrition."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/QAD.0000000000000599","article-title":"Human adipose tissue as a reservoir for memory cd4+ t cells and hiv","volume":"29","author":"Couturier","year":"2015","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11904-018-0378-z","article-title":"Hiv persistence in adipose tissue reservoirs","volume":"15","author":"Couturier","year":"2018","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.bbrep.2025.102345_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670566","article-title":"Contribution of adipose tissue to the chronic immune activation and inflammation associated with hiv infection and its treatment","volume":"12","author":"Bourgeois","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3851\/IMP2021","article-title":"Hiv-1 tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human sgbs adipocytes","volume":"17","author":"D\u00edaz-Delf\u00edn","year":"2012","journal-title":"Antivir. Ther."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with hiv : a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102345_bib37","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/jac\/dky145","article-title":"Obesity following art initiation is common and influenced by both traditional and hiv-\/art-specific risk factors","volume":"73","author":"Bakal","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.beem.2010.10.017","article-title":"Molecular mechanisms for insulin resistance in treated hiv-infection","volume":"25","author":"Hruz","year":"2011","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/endrev\/bnad028","article-title":"Adipose tissue dysfunction and energy balance paradigms in people living with hiv","volume":"45","author":"Ramirez Bustamante","year":"2024","journal-title":"Endocr. Rev."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102345_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165838","article-title":"Mitochondrial dysfunction in metabolic syndrome","volume":"1866","author":"Prasun","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jjcc.2013.11.006","article-title":"Adipokines: a link between obesity and cardiovascular disease","volume":"63","author":"Nakamura","year":"2014","journal-title":"J. Cardiol."},{"key":"10.1016\/j.bbrep.2025.102345_bib42","first-page":"50","article-title":"Obesity, inflammation, and insulin resistance","author":"Martins","year":"2014","journal-title":"Brazilian J. Pharmaceuti. Sci."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jmb.2019.09.016","article-title":"Recent insights into mechanisms of \u03b2-cell lipo- and glucolipotoxicity in type 2 diabetes","volume":"432","author":"Lytrivi","year":"2020","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib44","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/ijms12053117","article-title":"Inflammation, oxidative stress, and obesity","volume":"12","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","article-title":"Role of mitochondrial dysfunction in insulin resistance","volume":"102","author":"Kim","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbrep.2025.102345_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110691","article-title":"Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions","volume":"200","author":"Suren Garg","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"Suppl 2","key":"10.1016\/j.bbrep.2025.102345_bib47","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.2337\/dc09-S340","article-title":"Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin","volume":"32","author":"Esteve","year":"2009","journal-title":"Diabetes Care."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102345_bib48","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2337\/dc15-2113","article-title":"\u201cPrediabetes\u201d: are there problems with this label? Yes, the label creates further problems","volume":"39","author":"Yudkin","year":"2016","journal-title":"Diabetes Care."},{"issue":"9","key":"10.1016\/j.bbrep.2025.102345_bib49","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1373\/clinchem.2019.307611","article-title":"Is a prediabetes diagnosis worth the risk?","volume":"65","author":"McShane","year":"2019","journal-title":"Clin. Chem."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102345_bib50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/1535370220915644","article-title":"Regression from prediabetes to normal glucose regulation: state of the science","volume":"245","author":"Sallar","year":"2020","journal-title":"Experimental Biology. Medicine."},{"issue":"6431","key":"10.1016\/j.bbrep.2025.102345_bib51","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.363.6431.1026","article-title":"Dubious diagnosis","volume":"363","author":"Piller","year":"2019","journal-title":"Science."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102345_bib52","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2337\/dc16-1143","article-title":"\u201cPrediabetes\u201d: are there problems with this label? No, we need heightened awareness of this condition","volume":"39","author":"Cefalu","year":"2016","journal-title":"Diabetes Care."},{"issue":"10365","key":"10.1016\/j.bbrep.2025.102345_bib53","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"issue":"10397","key":"10.1016\/j.bbrep.2025.102345_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib55","first-page":"2568","article-title":"National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the united states, 2011","volume":"201","year":"2011","journal-title":"US department of health and human services, centers for disease control and prevention"},{"issue":"7","key":"10.1016\/j.bbrep.2025.102345_bib56","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2337\/dc22-2376","article-title":"Global prevalence of prediabetes","volume":"46","author":"Rooney","year":"2023","journal-title":"Diabetes Care."},{"key":"10.1016\/j.bbrep.2025.102345_bib57","series-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a who\/idf Consultation","year":"2006"},{"issue":"Supplement_1","key":"10.1016\/j.bbrep.2025.102345_bib58","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"Association","year":"2013","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.bbrep.2025.102345_bib59","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"Association","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4239\/wjd.v6.i2.296","article-title":"Prediabetes diagnosis and treatment: a review","volume":"6","author":"Bansal","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.bbrep.2025.102345_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2023.1181729","article-title":"Progression from prediabetes to type 2 diabetes mellitus in adolescents: a real world experience","volume":"4","author":"Weiner","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"issue":"21","key":"10.1016\/j.bbrep.2025.102345_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218178","article-title":"Prevention of diabetes and cardiovascular disease in obesity","volume":"21","author":"La Sala","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102345_bib63","article-title":"Multi-omics approaches for biomarker discovery and precision diagnosis of prediabetes","volume":"16","author":"Song","year":"2025","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib64","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/dc05-2179","article-title":"Contributions of \u03b2-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.bbrep.2025.102345_bib65","article-title":"Hyperinsulinemia and ectopic fat: it is time for a paradigm shift in the management of type 2 diabetes","volume":"25","author":"Overnutrition","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102345_bib66","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrep.2025.102345_bib67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmet.2018.04.006","article-title":"Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intolerance","volume":"12","author":"Pepin","year":"2018","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11904-018-0399-7","article-title":"Factors associated with insulin resistance in adults with hiv receiving contemporary antiretroviral therapy: a brief update","volume":"15","author":"Hulgan","year":"2018","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.bbrep.2025.102345_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.807632","article-title":"Pancreas-its functions, disorders, and physiological impact on the mammals' organism","volume":"13","author":"Karpi\u0144ska","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrep.2025.102345_bib70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (gip and glp\u20101) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib71","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1210\/en.2006-0057","article-title":"Minireview: implication of mitochondria in insulin secretion and action","volume":"147","author":"Wiederkehr","year":"2006","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.bbrep.2025.102345_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.tem.2012.06.002","article-title":"Mitochondrial dysfunction in pancreatic \u03b2 cells","volume":"23","author":"Supale","year":"2012","journal-title":"Trends Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib73","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/febs.16306","article-title":"Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk","volume":"290","author":"Sanches","year":"2023","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib74","doi-asserted-by":"crossref","DOI":"10.2174\/18756417MTEx6MTQpx","article-title":"Glucolipotoxicity-induced oxidative stress is related to mitochondrial dysfunction and apoptosis of pancreatic \u03b2-cell","volume":"17","author":"Vela-Guajardo","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.bbrep.2025.102345_bib75","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1007\/s00125-020-05210-8","article-title":"A tale of two pancreases: exocrine pathology and endocrine dysfunction","volume":"63","author":"Rickels","year":"2020","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13041179","article-title":"Interactions between the exocrine and the endocrine pancreas","volume":"13","author":"Valente","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbrep.2025.102345_bib77","doi-asserted-by":"crossref","DOI":"10.1590\/s0004-2803.24612024-070","article-title":"Association of \u201cmetabolic dysfunction-associated steatotic pancreas disease\u201d(maspd) and insulin resistance","volume":"61","author":"Andrade","year":"2024","journal-title":"Arq. Gastroenterol."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib78","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/sjmms.sjmms_526_23","article-title":"Extended review and updates of nonalcoholic fatty pancreas disease","volume":"12","author":"Habas","year":"2024","journal-title":"Saudi J Med Med Sci"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib79","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (masld): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"24","key":"10.1016\/j.bbrep.2025.102345_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413238","article-title":"The causal role of ectopic fat deposition in the pathogenesis of metabolic syndrome","volume":"25","author":"Janssen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.bbrep.2025.102345_bib81","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.12998\/wjcc.v9.i23.6624","article-title":"Nonalcoholic fatty pancreas disease: an emerging clinical challenge","volume":"9","author":"Zhang","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.bbrep.2025.102345_bib82","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2439","article-title":"Fatty pancreas: disease or finding?","volume":"76","author":"Silva","year":"2021","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1475-2840-12-77","article-title":"Association between non-alcoholic fatty pancreatic disease (nafpd) and the metabolic syndrome: case\u2013control retrospective study","volume":"12","author":"Wu","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbrep.2025.102345_bib84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1590\/s0004-2803.202000000-27","article-title":"Pancreatic steatosis: a new diagnosis and therapeutic challenge in gastroenterology","volume":"57","author":"Paul","year":"2020","journal-title":"Arq. Gastroenterol."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib85","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db21-0976","article-title":"Fat distribution within the pancreas according to diabetes status and insulin traits","volume":"71","author":"Skudder-Hill","year":"2022","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.bbrep.2025.102345_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180911","article-title":"Pancreatic size and fat content in diabetes: a systematic review and meta-analysis of imaging studies","volume":"12","author":"Garcia","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2014.5","article-title":"Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma","volume":"5","author":"Hori","year":"2014","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1468-1293.2012.01047.x","article-title":"Pancreatic insufficiency in patients with hiv infection: role of didanosine questioned","volume":"14","author":"Martin","year":"2013","journal-title":"HIV Med."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib89","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1590\/S1679-45082014RW2561","article-title":"Antiretroviral drugs and acute pancreatitis in hiv\/aids patients: is there any association? A literature review","volume":"12","author":"Oliveira","year":"2014","journal-title":"Einstein (Sao Paulo)"},{"issue":"12","key":"10.1016\/j.bbrep.2025.102345_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/biology9120473","article-title":"Incretin hormones and type 2 diabetes-mechanistic insights and therapeutic approaches","volume":"9","author":"Boer","year":"2020","journal-title":"Biology"},{"key":"10.1016\/j.bbrep.2025.102345_bib91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijbiomac.2017.05.190","article-title":"Studies on glycoxidatively modified human igg: implications in immuno-pathology of type 2 diabetes mellitus","volume":"104","author":"Islam","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrep.2025.102345_bib92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib93","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/nu13020351","article-title":"Incretin hormones in obesity and related cardiometabolic disorders: the clinical perspective","volume":"13","author":"Micha\u0142owska","year":"2021","journal-title":"Nutrients"},{"issue":"Suppl 3","key":"10.1016\/j.bbrep.2025.102345_bib94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (gip and glp-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrep.2025.102345_bib95","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fimmu.2015.00386","article-title":"Dpp4 in diabetes","volume":"6","author":"R\u00f6hrborn","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2025.102345_bib96","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/j.ejim.2009.05.012","article-title":"Unraveling the science of incretin biology","volume":"20","author":"Nauck","year":"2009","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/edn.221","article-title":"Incretin therapy for type 2 diabetes: Glp-1 receptor agonists and dpp-4 inhibitors","volume":"10","author":"Ahr\u00e9n","year":"2013","journal-title":"Eur. Diabetes Nurs."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.14211","article-title":"Incretins in obesity and diabetes","volume":"1461","author":"Chia","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1468-1293.2005.00270.x","article-title":"Enhanced glucagon\u2010like peptide\u20101 (glp\u20101) response to oral glucose in glucose\u2010intolerant hiv\u2010infected patients on antiretroviral therapy","volume":"6","author":"Andersen","year":"2005","journal-title":"HIV Med."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3390\/jcm11061713","article-title":"Effect of combined antiretroviral therapy on the levels of selected parameters reflecting metabolic and inflammatory disturbances in hiv-infected patients","volume":"11","author":"Jurkowska","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbrep.2025.102345_bib101","first-page":"1","article-title":"Hiv life cycle: overview","author":"Kirchhoff","year":"2013","journal-title":"Encyclopedia of AIDS"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","article-title":"The impact of medication regimen factors on adherence to chronic treatment: a review of literature","volume":"31","author":"Ingersoll","year":"2008","journal-title":"J. Behav. Med."},{"issue":"9635","key":"10.1016\/j.bbrep.2025.102345_bib103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","author":"Collaboration","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.14740\/jem364w","article-title":"Highly active antiretroviral therapy-associated metabolic syndrome and lipodystrophy: pathophysiology and current therapeutic interventions","volume":"7","author":"Nzuza","year":"2017","journal-title":"Journal of Endocrinology and Metabolism"},{"issue":"9491","key":"10.1016\/j.bbrep.2025.102345_bib105","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome--a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbrep.2025.102345_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijregi.2025.100679","article-title":"Prevalence of metabolic diseases in patients infected with hiv receiving antiretroviral therapy at sultan qaboos university hospital, oman","volume":"16","author":"Alwahibia","year":"2025","journal-title":"IJID Regions"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib107","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1186\/s12889-024-20118-3","article-title":"Burden of metabolic syndrome in the global adult hiv-infected population: a systematic review and meta-analysis","volume":"24","author":"Trachunthong","year":"2024","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib108","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"Fahed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.hivar.2014.09.002","article-title":"Metabolic syndrome in hiv-positive patients","volume":"14","author":"Drelichowska","year":"2015","journal-title":"HIV & AIDS Review"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11904-013-0191-7","article-title":"Metabolic consequences of hiv: pathogenic insights","volume":"11","author":"Willig","year":"2014","journal-title":"Curr. HIV AIDS Rep."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib111","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-6405-10-32","article-title":"Metabolic syndrome in hiv-infected individuals: underlying mechanisms and epidemiological aspects","volume":"10","author":"Paula","year":"2013","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.bbrep.2025.102345_bib112","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7316456","article-title":"Hiv-related immune activation and inflammation: current understanding and strategies","volume":"2021","author":"Lv","year":"2021","journal-title":"J Immunol Res"},{"issue":"16","key":"10.1016\/j.bbrep.2025.102345_bib113","first-page":"540","article-title":"Hiv and pancreas in the haart era: endocrinological patterns","volume":"16","author":"Marques","year":"2015","journal-title":"J. Pancreas"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib114","article-title":"Endocrine and metabolic disorders associated with human immune deficiency virus infection","volume":"28","author":"Unachukwu","year":"2009","journal-title":"W. Afr. J. Med."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual hiv transmission in botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bbrep.2025.102345_bib116","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"Hiv preexposure prophylaxis: a review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bbrep.2025.102345_bib117","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1054-3589(07)56005-9","article-title":"Inhibitors of hiv\u20101 reverse transcriptase","author":"Ilina","year":"2008"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib118","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.bbrep.2025.102345_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114554","article-title":"Hiv nucleoside reverse transcriptase inhibitors","volume":"240","author":"Amblard","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of hiv medications","volume":"10","author":"Margolis","year":"2014","journal-title":"J. Med. Toxicol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib121","first-page":"371","article-title":"Antiretroviral therapy: current drugs","volume":"28","author":"Pau","year":"2014","journal-title":"Infect. Dis. Clin."},{"key":"10.1016\/j.bbrep.2025.102345_bib122","article-title":"A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide","volume":"19","author":"Wassner","year":"2020","journal-title":"J. Int. Assoc. Phys. AIDS Care"},{"key":"10.1016\/j.bbrep.2025.102345_bib123","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of hiv-1 infection: a meta-analysis of randomized controlled trials","volume":"93","author":"Tao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"Journal of Virus Eradication"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib127","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","article-title":"How safe is tdf\/ftc as prep? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of prep","volume":"4","author":"Pilkington","year":"2018","journal-title":"Journal of Virus Eradication"},{"issue":"10246","key":"10.1016\/j.bbrep.2025.102345_bib128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for hiv pre-exposure prophylaxis (discover): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (nnrtis), their discovery, development, and use in the treatment of hiv-1 infection: a review of the last 20 years (1989\u20132009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102345_bib130","first-page":"67","article-title":"The urgent need for more potent antiretroviral therapy in low-income countries to achieve unaids 90-90-90 and complete eradication of aids by 2030","volume":"8","author":"Ndashimye","year":"2019","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.bbrep.2025.102345_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"Cyp2b6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib132","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41397-018-0028-2","article-title":"Polymorphisms in cytochrome p450 are associated with extensive efavirenz pharmacokinetics and cns toxicities in an hiv cohort in botswana","volume":"18","author":"Vujkovic","year":"2018","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib133","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4102\/sajhivmed.v18i1.741","article-title":"Efavirenz and neuropsychiatric effects","volume":"18","author":"Dheda","year":"2017","journal-title":"South. Afr. J. HIV Med."},{"issue":"9927","key":"10.1016\/j.bbrep.2025.102345_bib134","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in hiv-infected, antiretroviral-naive adults (encore1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051212","article-title":"Liver fibrosis during antiretroviral treatment in hiv-infected individuals. Truth or tale?","volume":"10","author":"Bakasis","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010174","article-title":"The impact of hiv- and art-induced mitochondrial dysfunction in cellular senescence and aging","volume":"10","author":"Schank","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib140","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, hiv-1 patients in two phase iii randomized trials","volume":"27","author":"Cohen","year":"2013","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib142","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25862","article-title":"Switching efavirenz to rilpivirine in virologically suppressed adolescents with hiv: a multi-centre 48-week efficacy and safety study in thailand","volume":"25","author":"Phongsamart","year":"2022","journal-title":"J. Int. AIDS Soc."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib143","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/ijms24032890","article-title":"Evolution of antiretroviral drug rilpivirine and approach to oncology","volume":"24","author":"Pereira","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102345_bib144","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive hiv-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib145","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QAD.0000000000000911","article-title":"Rilpivirine vs. Efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study","volume":"30","author":"van Lunzen","year":"2016","journal-title":"Aids"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102345_bib148","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02016-18","article-title":"Doravirine and the potential for cyp3a-mediated drug-drug interactions","volume":"63","author":"Khalilieh","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102345_bib149","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40261-020-00934-2","article-title":"Clinical pharmacokinetics of the novel hiv-1 non-nucleoside reverse transcriptase inhibitor doravirine: an assessment of the effect of patient characteristics and drug-drug interactions","volume":"40","author":"Khalilieh","year":"2020","journal-title":"Clin. Drug Invest."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib151","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/QAD.0000000000002725","article-title":"Changes in weight and bmi with first-line doravirine-based therapy","volume":"35","author":"Orkin","year":"2021","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib152","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1060028019869641","article-title":"Doravirine: a return of the nnrti class?","volume":"54","author":"Blevins","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102345_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11020197","article-title":"Metabolic complications of chronic hiv infection: a narrative review","volume":"11","author":"Cummins","year":"2022","journal-title":"Pathogens"},{"issue":"Suppl 1","key":"10.1016\/j.bbrep.2025.102345_bib158","first-page":"S15","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.bbrep.2025.102345_bib159","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc09-0177","article-title":"A1c underestimates glycemia in hiv infection","volume":"32","author":"Kim","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.bbrep.2025.102345_bib160","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1093\/jac\/dku295","article-title":"Inaccuracy of haemoglobin a1c among hiv-infected men: effects of cd4 cell count, antiretroviral therapies and haematological parameters","volume":"69","author":"Slama","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbrep.2025.102345_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101283","article-title":"Prevalence of anemia among people living with hiv: a systematic review and meta-analysis","volume":"44","author":"Cao","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102345_bib162","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12981-020-00284-1","article-title":"Prediabetes among hiv-infected individuals receiving antiretroviral therapy: prevalence, diagnostic tests, and associated factors","volume":"17","author":"Phuphuakrat","year":"2020","journal-title":"AIDS Res. Ther."},{"issue":"9","key":"10.1016\/j.bbrep.2025.102345_bib163","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1345\/aph.19075","article-title":"Pharmacologic considerations for therapeutic success with antiretroviral agents","volume":"33","author":"Fletcher","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bbrep.2025.102345_bib164","first-page":"9","article-title":"Pharmacological considerations in antiretroviral therapy","volume":"3","author":"Sommadossi","year":"1998","journal-title":"Antivir. Ther."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102345_bib165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","article-title":"Drug resistance during hiv pre-exposure prophylaxis","volume":"79","author":"Gibas","year":"2019","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib166","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ecl.2021.05.005","article-title":"Prevention of microvascular complications of diabetes","volume":"50","author":"Crasto","year":"2021","journal-title":"Endocrinol. Metabol. Clin"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102345_bib167","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/cid\/ciu779","article-title":"Diagnosing and managing diabetes in hiv-infected patients: current concepts","volume":"60","author":"Monroe","year":"2014","journal-title":"Clin. Infect. Dis."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825004327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825004327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:58:24Z","timestamp":1773802704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825004327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":167,"alternative-id":["S2405580825004327"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102345","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102345"}}